TY - JOUR
T1 - B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma
T2 - a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)
AU - Balzarotti, Monica
AU - Brusamolino, Ercole
AU - Angelucci, E.
AU - Carella, Angelo Michele
AU - Vitolo, U.
AU - Russo, Eleonora
AU - Congiu, Angelagiovanna
AU - Gotti, Manuel
AU - Massidda, Stefania
AU - Botto, B.
AU - Annechini, Giorgia
AU - Spina, Michele
AU - Re, Alessandro
AU - Zilioli, Vittorio Ruggero
AU - Merli, Francesco
AU - Salvi, Flavia
AU - Stelitano, Caterina
AU - Bonfichi, Maurizio
AU - Rodari, Marcello
AU - Murru, Roberta
AU - Magagnoli, Massimo
AU - Anastasia, Antonella
AU - Mazza, Rita
AU - Giordano, Laura
AU - Santoro, Armando
PY - 2016/2/12
Y1 - 2016/2/12
N2 - This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p
AB - This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p
KW - Chemotherapeutic approaches
KW - clinical results
KW - lymphoma and Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84958544689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958544689&partnerID=8YFLogxK
U2 - 10.3109/10428194.2016.1140161
DO - 10.3109/10428194.2016.1140161
M3 - Article
SP - 2375
EP - 2381
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
ER -